• European Medicines Agency validated two Daiichi Sankyo marketing authorization applications for single-pill, triple-combination lipid-lowering therapies in the EU.
• If approved, the treatments could become the EU’s first oral single-pill triple combinations for lowering cholesterol.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290727BIZWIRE_USPR_____20261029_BW012837) on October 29, 2026, and is solely responsible for the information contained therein.